Genmab A/S - American Depositary Shares (NQ:GMAB)

57.29 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches ↗

October 28, 2026

Genmab A/S (NASDAQ:GMAB) said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the...

Via MarketBeat

Top US Stock Movers in Today's Session ↗

October 28, 2026

Via Chartmill

US Top Movers: Biggest Gainers and Decliners in Today's Session ↗

October 28, 2026

Via Chartmill

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

October 28, 2026

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) Eyes Breakout as Technical Strength Builds ↗

October 20, 2026

Via Chartmill

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market

October 26, 2026

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

October 26, 2026

From Genmab A/S

Via Business Wire

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

October 25, 2026

From Genmab A/S

Via Business Wire

Genmab (GMAB) Posts Perfect Technical and Setup Scores in Breakout Setup ↗

August 01, 2026

Via Chartmill

Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case ↗

March 05, 2026

Via Chartmill

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

October 24, 2026

From Genmab A/S

Via Business Wire

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

October 23, 2026

From Genmab A/S

Via Business Wire

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

October 05, 2026

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP Investment ↗

February 20, 2026

Via Chartmill

Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth ↗

February 06, 2026

Via Chartmill

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

October 03, 2026

From Genmab A/S

Via Business Wire

Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4 ↗

September 26, 2026

Genmab A/S (NASDAQ:GMAB) expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities,...

Via MarketBeat

Genmab (GMAB) Q2 2026 Earnings Call Transcript ↗

August 06, 2026

Revenue guidance raised to $4.3B–$4.5B as non-DARZALEX products drive half of growth.

Via The Motley Fool

Topics Earnings

GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment ↗

January 29, 2026

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation ↗

January 26, 2026

Via Chartmill

Genmab A/S Q2 Earnings Call Highlights ↗

August 06, 2026

Genmab A/S (NASDAQ:GMAB) reported first-half 2026 revenue growth of 25% year over year and raised its full-year financial outlook, citing continued momentum from DARZALEX, EPKINLY and the broader...

Via MarketBeat

Topics Earnings

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

July 23, 2026

From Genmab A/S and AbbVie

Via Business Wire

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

July 06, 2026

From Genmab A/S

Via Business Wire

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

June 29, 2026

From Genmab A/S

Via Business Wire

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

June 13, 2026

From Genmab A/S

Via Business Wire

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

June 11, 2026

From Genmab

Via Business Wire

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

May 21, 2026

From Genmab A/S

Via Business Wire

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

April 13, 2026

From Genmab A/S

Via Business Wire

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.

Via The Motley Fool

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based...

Via MarketMinute

Topics ETFs Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.